DVA · Company research
DaVita Inc. (DVA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know - Yahoo Finance | DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know | DaVita HealthCare (DVA) closed at $187.25, down 1.01% in the latest session but outperforming the S&P 500's 1.09% decline. The kidney dialysis provider is forecasted to report EPS of $3.78 (up 50.6% YoY) with revenue expected at $3.53 billion (up 3.23% YoY). Trading at a Forward P/E of 12.98 versus the industry average of 20.96, DVA appears undervalued. The stock holds a Zacks Rank #3 (Hold) with a PEG ratio of 0.49, significantly below the industry average of 1.82. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| DaVita Inc. (DVA) Stock Forecasts - Yahoo! Finance Canada | DaVita Inc. (DVA) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| DaVita Inc. (DVA) Stock Price, News, Quote & History - Yahoo! Finance Canada | DaVita Inc. (DVA) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Why patients miss dialysis is one focus of seven studies DaVita will present. - Stock Titan | Why patients miss dialysis is one focus of seven studies DaVita will present. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance | DaVita Inc. (DVA) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Why DaVita HealthCare (DVA) Outpaced the Stock Market Today - Yahoo! Finance Canada | Why DaVita HealthCare (DVA) Outpaced the Stock Market Today Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Why DaVita HealthCare (DVA) Outpaced the Stock Market Today | DaVita HealthCare (DVA) closed at $179.25, up 1.26% and outperforming the S&P 500. The kidney dialysis provider is projected to report 50.6% EPS growth and 3.23% revenue growth in the upcoming quarter, with full-year estimates showing 35.16% earnings growth. Trading at a Forward P/E of 12.15 (below industry average of 20.06) and a PEG ratio of 0.46, DVA holds a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA) - Seeking Alpha | DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 9, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain DaVita Stock in Your Portfolio for Now | DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Retain DaVita Stock in Your Portfolio for Now | DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Did Storm Response Activation Just Shift DaVita (DVA) Stock Investment Narrative? - Simply Wall Street | Did Storm Response Activation Just Shift DaVita (DVA) Stock Investment Narrative? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance | DaVita Inc. (DVA) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| Strength Seen in Option Care (OPCH): Can Its 32.7% Jump Turn into More Strength? | Option Care Health (OPCH) surged 32.7% following the announcement of its acquisition by CD&R and McKesson for $32.05 per share in cash, representing a 37% premium to the previous closing price. The $5.8 billion enterprise value deal underscores the strategic appeal of OPCH's home and alternate-site infusion care platform. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that sustained momentum may depend on future estimate trends. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.5 | 1 |
| DaVita HealthCare (DVA) Laps the Stock Market: Here's Why - Yahoo Finance | DaVita HealthCare (DVA) Laps the Stock Market: Here's Why Yahoo Finance | View source ↗ | Yahoo Finance | Oct 2, 2026 | neutral | 0 | 0.6 |
| DaVita (DVA) Stock May Be Undervalued On Its Earnings Power - Yahoo Finance | DaVita (DVA) Stock May Be Undervalued On Its Earnings Power Yahoo Finance | View source ↗ | Yahoo Finance | Sep 29, 2026 | neutral | 0 | 0.6 |
| 1 Profitable Stock with Competitive Advantages and 2 That Underwhelm - StockStory | 1 Profitable Stock with Competitive Advantages and 2 That Underwhelm StockStory | View source ↗ | StockStory | Sep 23, 2026 | neutral | 0 | 0.6 |
| DaVita Stock Drops Despite Reporting Strong Q2 Results and Solid Guidance - TIKR.com | DaVita Stock Drops Despite Reporting Strong Q2 Results and Solid Guidance TIKR.com | View source ↗ | TIKR.com | Aug 5, 2026 | neutral | 0 | 0.6 |
| DVA Q2 Deep Dive: Flat Volumes and Policy Transitions Shape Outlook - StockStory | DVA Q2 Deep Dive: Flat Volumes and Policy Transitions Shape Outlook StockStory | View source ↗ | StockStory | Aug 5, 2026 | neutral | 0 | 0.6 |
| DaVita (DVA) Stock Price Faces Margin Doubts After 17% Sell Off - Simply Wall Street | DaVita (DVA) Stock Price Faces Margin Doubts After 17% Sell Off Simply Wall Street | View source ↗ | Simply Wall Street | Aug 5, 2026 | neutral | 0 | 0.6 |
| DaVita (NYSE:DVA) Beats Q2 CY2026 Sales Expectations But Stock Drops - Yahoo Finance | DaVita (NYSE:DVA) Beats Q2 CY2026 Sales Expectations But Stock Drops Yahoo Finance | View source ↗ | Yahoo Finance | Aug 4, 2026 | neutral | 0 | 0.6 |
| DaVita (DVA) Stock After 82% YTD Surge Is The Price Still Justified - Yahoo Finance | DaVita (DVA) Stock After 82% YTD Surge Is The Price Still Justified Yahoo Finance | View source ↗ | Yahoo Finance | Jun 14, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.